MedTrace Logo

Calcinosis Reduction by Pyrophosphate in SSC

NCT04966416 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-05-25

No results posted yet for this study

Summary

Calcinosis, i.e. crystal-like nodules are troublesome complication of systemic sclerosis, an autoimmune disease. Pyrophosphate inhibits its formation is laborytory. We would like to test if orally administered pyrophosphate prevents calcinosis formation.

Conditions

Interventions

DIETARY_SUPPLEMENT

Pyrophosphate

50 mg/kg bwt once daily in gelatine capsules.

DIETARY_SUPPLEMENT

Placebo

Glucose in gelatine capsules.

Sponsors & Collaborators

  • Research Centre for Natural Sciences

    collaborator OTHER

  • University of Debrecen Dept. of Rheumatology

    collaborator UNKNOWN

  • Szeged University

    lead OTHER

Principal Investigators

  • László Kovács, MD, Ph.D. · Szeged University

  • András Váradi, PhD, DSc · Department of Enzymology, Research Centre for Natural Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2025-06-30
Completion
2026-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04966416 on ClinicalTrials.gov